Alemtuzumab: Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation?

S. Schneeberger; L. Landin; C. Kaufmann; V. S. Gorantla; G. Brandacher; P. Cavadas; W. P.A. Lee; W. C. Breidenbach; R. Margreiter

doi:10.1016/j.transproceed.2009.01.018

Alemtuzumab: Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation?

S. Schneeberger
, L. Landin
, C. Kaufmann
, V. S. Gorantla
, G. Brandacher
, P. Cavadas
, W. P.A. Lee
, W. C. Breidenbach
, R. Margreiter

Surgery

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Minimization of immunosuppression has become the key effort in solid organ transplantation. Alemtuzumab, the humanized CD-52 monoclonal antibody, is an effective depleting agent increasingly used in transplantation trials. In this article, we summarize the current experience with alemtuzumab use in hand transplantation and discuss its role in current and future approaches toward minimization of maintenance immunosuppression in reconstructive transplantation.

Original language	English (US)
Pages (from-to)	499-502
Number of pages	4
Journal	Transplantation Proceedings
Volume	41
Issue number	2
DOIs	https://doi.org/10.1016/j.transproceed.2009.01.018
State	Published - Mar 2009

ASJC Scopus subject areas

Surgery
Transplantation

Access to Document

10.1016/j.transproceed.2009.01.018

Cite this

@article{d6beb3cf449c400f8214a4c92d327fb6,

title = "Alemtuzumab: Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation?",

abstract = "Minimization of immunosuppression has become the key effort in solid organ transplantation. Alemtuzumab, the humanized CD-52 monoclonal antibody, is an effective depleting agent increasingly used in transplantation trials. In this article, we summarize the current experience with alemtuzumab use in hand transplantation and discuss its role in current and future approaches toward minimization of maintenance immunosuppression in reconstructive transplantation.",

author = "S. Schneeberger and L. Landin and C. Kaufmann and Gorantla, \{V. S.\} and G. Brandacher and P. Cavadas and Lee, \{W. P.A.\} and Breidenbach, \{W. C.\} and R. Margreiter",

note = "Funding Information: Supported by TILAK Foundation, Innsbruck, Austria, and by the US Army Medical Research and Marteriel Command under Award No. W81XWH-07-1-0185, and the US Office of Navy Research under Award No. N000140610084. Opinions, interpretations, conclusions and recommendations are those of the authors and not necessarily endorsed by the US Army or the US Navy. ",

year = "2009",

month = mar,

doi = "10.1016/j.transproceed.2009.01.018",

language = "English (US)",

volume = "41",

pages = "499--502",

journal = "Transplantation Proceedings",

issn = "0041-1345",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Alemtuzumab

T2 - Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation?

AU - Schneeberger, S.

AU - Landin, L.

AU - Kaufmann, C.

AU - Gorantla, V. S.

AU - Brandacher, G.

AU - Cavadas, P.

AU - Lee, W. P.A.

AU - Breidenbach, W. C.

AU - Margreiter, R.

N1 - Funding Information: Supported by TILAK Foundation, Innsbruck, Austria, and by the US Army Medical Research and Marteriel Command under Award No. W81XWH-07-1-0185, and the US Office of Navy Research under Award No. N000140610084. Opinions, interpretations, conclusions and recommendations are those of the authors and not necessarily endorsed by the US Army or the US Navy.

PY - 2009/3

Y1 - 2009/3

N2 - Minimization of immunosuppression has become the key effort in solid organ transplantation. Alemtuzumab, the humanized CD-52 monoclonal antibody, is an effective depleting agent increasingly used in transplantation trials. In this article, we summarize the current experience with alemtuzumab use in hand transplantation and discuss its role in current and future approaches toward minimization of maintenance immunosuppression in reconstructive transplantation.

AB - Minimization of immunosuppression has become the key effort in solid organ transplantation. Alemtuzumab, the humanized CD-52 monoclonal antibody, is an effective depleting agent increasingly used in transplantation trials. In this article, we summarize the current experience with alemtuzumab use in hand transplantation and discuss its role in current and future approaches toward minimization of maintenance immunosuppression in reconstructive transplantation.

UR - https://www.scopus.com/pages/publications/62849099728

UR - https://www.scopus.com/pages/publications/62849099728#tab=citedBy

U2 - 10.1016/j.transproceed.2009.01.018

DO - 10.1016/j.transproceed.2009.01.018

M3 - Article

C2 - 19328912

AN - SCOPUS:62849099728

SN - 0041-1345

VL - 41

SP - 499

EP - 502

JO - Transplantation Proceedings

JF - Transplantation Proceedings

IS - 2

ER -

Alemtuzumab: Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this